Sugar chain marker as measure of disease conditions of hepatic diseases
作者： Takashi Angata , Makoto Ochou , Hisashi Narimatsu , Yuzuru Ikehara , Toshihide Shikanai
DOI:
关键词:
摘要: Disclosed is a sugar chain marker which can detect hepatic diseases. More specifically disclosed be used as measure of the disease conditions Further distinguish depending on stages progression hepatocellular carcinoma. A glycopeptide and group glycopeptides structure changed in diseases including carcinoma are identified among from serum glycoproteins. The novel (glycopeptides glycoprotein) specific to
lens.org 参考文章(16)
Y. Ihara, M. Yoshimura, E. Miyoshi, A. Nishikawa, A. S. Sultan, S. Toyosawa, A. Ohnishi, M. Suzuki, K.-i. Yamamura, N. Ijuhin, N. Taniguchi, Ectopic expression of N-acetylglucosaminyltransferase III in transgenic hepatocytes disrupts apolipoprotein B secretion and induces aberrant cellular morphology with lipid storage Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 2526- 2530 ,(1998) , 10.1073/PNAS.95.5.2526
Timothy M. Block, Mary Ann Comunale, Anand Mehta, Diagnosis of liver pathology through assessment of protein glycosylation ,(2006)
Hiromi Ito, Atsushi Kuno, Hiromichi Sawaki, Maki Sogabe, Hidenori Ozaki, Yasuhito Tanaka, Masashi Mizokami, Jun-ichi Shoda, Takashi Angata, Takashi Sato, Jun Hirabayashi, Yuzuru Ikehara, Hisashi Narimatsu, Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. Journal of Proteome Research. ,vol. 8, pp. 1358- 1367 ,(2009) , 10.1021/PR800735J
Hiroyuki Kaji, Yoshio Yamauchi, Nobuhiro Takahashi, Toshiaki Isobe, Mass spectrometric identification of N -linked glycopeptides using lectin-mediated affinity capture and glycosylation site–specific stable isotope tagging Nature Protocols. ,vol. 1, pp. 3019- 3027 ,(2006) , 10.1038/NPROT.2006.444
Bram Blomme, Christophe Van Steenkiste, Nico Callewaert, Hans Van Vlierberghe, Alteration of protein glycosylation in liver diseases. Journal of Hepatology. ,vol. 50, pp. 592- 603 ,(2009) , 10.1016/J.JHEP.2008.12.010
Stefania Basili, Paola Andreozzi, Mario Vieri, Marina Maurelli, Doloretta Cara, Corrado Cordova, Cesare Alessandri, Lipoprotein (a) serum levels in patients with hepatocarcinoma. Clinica Chimica Acta. ,vol. 262, pp. 53- 60 ,(1997) , 10.1016/S0009-8981(97)06533-9
Houda Hachem, Gilles Favre, Gérard Raynal, Gisèle Blavy, Pierre Canal, Georges Soula, Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis. Clinical Chemistry and Laboratory Medicine. ,vol. 24, pp. 161- 166 ,(1986) , 10.1515/CCLM.1986.24.3.161
T. M. Block, M. A. Comunale, M. Lowman, L. F. Steel, P. R. Romano, C. Fimmel, B. C. Tennant, W. T. London, A. A. Evans, B. S. Blumberg, R. A. Dwek, T. S. Mattu, A. S. Mehta, Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 779- 784 ,(2005) , 10.1073/PNAS.0408928102
Akira Harazono, Nana Kawasaki, Toru Kawanishi, Takao Hayakawa, Site-specific glycosylation analysis of human apolipoprotein B100 using LC/ESI MS/MS. Glycobiology. ,vol. 15, pp. 447- 462 ,(2005) , 10.1093/GLYCOB/CWI033
Willy Morelle, Christophe Flahaut, Jean-Claude Michalski, Alexandre Louvet, Philippe Mathurin, André Klein, Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology. ,vol. 16, pp. 281- 293 ,(2006) , 10.1093/GLYCOB/CWJ067